Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Microvessel Density (MVD) and Cyclooxygenase-2 (COX-2)/β-Catenin Interaction Are Associated with Relapse in Patients with Transitional Carcinoma Receiving Adjuvant Chemotherapy with Paclitaxel/Carboplatin: A Hellenic Cooperative Oncology Group (HECOG) Study

A. BAMIAS, F. KYRIAKOU, M. CHORTI, N. KAVANTZAS, A. NONI, A. KYROUDI-VOULGARI, D. RONTOYIANNI, E. KASTRITIS, N. XIROS, E.S. PATSOURIS, S. MURRAY, N. TAMVAKIS and M.A. DIMOPOULOS
Anticancer Research July 2008, 28 (4C) 2479-2486;
A. BAMIAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: abamias@med.uoa.gr
F. KYRIAKOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. CHORTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. KAVANTZAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. NONI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. KYROUDI-VOULGARI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. RONTOYIANNI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. KASTRITIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. XIROS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.S. PATSOURIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. MURRAY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. TAMVAKIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.A. DIMOPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Cycloxygenase (COX)-2 has been associated with proliferation, apoptosis and angiogenesis in urothelial cancer. The prognostic significance of COX-2 in patients who received adjuvant chemotherapy for urothelial cancer was examined. Patients and Methods: Expression of COX-2, p53, ki67, β-catenin, vascular endothelial growth factor (VEGF) and microvessel density (MVD) were studied retrospectively in 59 patients with urothelial cancer (pT3, pT4, N+) who had undergone surgery. The patients had subsequently received adjuvant chemotherapy. Results: Thirty-eight out of 59 cases (64%) were positive for COX-2. COX-2 was not associated either with progression-free survival (PFS) or overall survival (OS). MVD levels ≥47 were associated with longer median PFS compared with lower levels (not reached vs. 13 months [95% CI: 8-18], p=0.048). The median PFS for patients with β-catenin nuclear accumulation and COX-2 expression was 6 months (95% CI: 4-7) compared with 19 months (95% CI: 14-23) for neither or only one of these factors (p=0.018). Conclusion: MVD may be a useful indicator of relapse in high-risk urothelial cancer treated with adjuvant chemotherapy.

  • Bladder cancer
  • MVD
  • CD105
  • COX-2
  • β-catenin

Footnotes

  • Received February 5, 2008.
  • Revision received May 5, 2008.
  • Accepted May 9, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Microvessel Density (MVD) and Cyclooxygenase-2 (COX-2)/β-Catenin Interaction Are Associated with Relapse in Patients with Transitional Carcinoma Receiving Adjuvant Chemotherapy with Paclitaxel/Carboplatin: A Hellenic Cooperative Oncology Group (HECOG) St…
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Microvessel Density (MVD) and Cyclooxygenase-2 (COX-2)/β-Catenin Interaction Are Associated with Relapse in Patients with Transitional Carcinoma Receiving Adjuvant Chemotherapy with Paclitaxel/Carboplatin: A Hellenic Cooperative Oncology Group (HECOG) Study
A. BAMIAS, F. KYRIAKOU, M. CHORTI, N. KAVANTZAS, A. NONI, A. KYROUDI-VOULGARI, D. RONTOYIANNI, E. KASTRITIS, N. XIROS, E.S. PATSOURIS, S. MURRAY, N. TAMVAKIS, M.A. DIMOPOULOS
Anticancer Research Jul 2008, 28 (4C) 2479-2486;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Microvessel Density (MVD) and Cyclooxygenase-2 (COX-2)/β-Catenin Interaction Are Associated with Relapse in Patients with Transitional Carcinoma Receiving Adjuvant Chemotherapy with Paclitaxel/Carboplatin: A Hellenic Cooperative Oncology Group (HECOG) Study
A. BAMIAS, F. KYRIAKOU, M. CHORTI, N. KAVANTZAS, A. NONI, A. KYROUDI-VOULGARI, D. RONTOYIANNI, E. KASTRITIS, N. XIROS, E.S. PATSOURIS, S. MURRAY, N. TAMVAKIS, M.A. DIMOPOULOS
Anticancer Research Jul 2008, 28 (4C) 2479-2486;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer
  • Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
  • Rare Upper Mediastinal Oligometastasis from Early Esophagogastric Adenocarcinoma: A Case Report
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire